SELECT PUBLICATIONS

Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract

Kim C et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 46.

Press MF et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (Herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium 2005;Abstract 1045.

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2005;Abstract 1.

Smith IE. Trastuzumab following adjuvant chemotherapy in HER2-positive early breast cancer (HERA trial): Disease-free and overall survival after 2 year median follow-up. Presentation. Proc ASCO 2006. Late-breaking scientific session. Abstract